BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
BC Innovations | Jan 6, 2017

NCATS: five, alive and kicking

  Born amid a flood of controversy from academics and companies alike, NIH 's National Center for Advancing Translational Sciences (NCATS) has endured to celebrate its fifth birthday last month. Director Chris Austin sat down...
BC Innovations | Apr 28, 2016

Bridging translation

An increasing number of academic institutions are filling the translational gap between what typical academic projects produce and what companies or VC firms want to see in order to commercialize a discovery. These organizations, or...
BioCentury | Sep 7, 2015

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BC Innovations | Aug 27, 2015

Abandoning linear thinking

Drug developers are coming to believe that a major rethink of the traditional bench-to-bedside model in early drug discovery might be the best way to bring down the high rates of clinical trial failures. At...
BC Innovations | Mar 20, 2014
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Autoimmune disease; cancer Proteasome In vitro studies identified belactosin A proteasome inhibitors with peptide boronate warheads that could help treat cancer or autoimmune diseases. In...
BC Innovations | Feb 27, 2014

Herding catalysts at UCSF

AstraZeneca plc has a burgeoning network of public-private partnerships, but until now the pharma has lacked a presence in the San Francisco Bay Area, one of the U.S.'s major hubs of life sciences innovation. AstraZeneca...
BC Innovations | Jan 30, 2014

NCATS two years later

The National Center for Advancing Translational Sciences (NCATS) was founded at the NIH a little over two years ago, in the wake of increasing concern over the slow pace of converting scientific discoveries into new...
BioCentury | Mar 12, 2012

Greasing the public-private interface

Bristol-Myers Squibb Co. and Duke University think their new partnership could be a model for other pharmas and universities to help speed all stages of drug development from preclinical research to post-marketing community outreach. BMS...
BC Extra | Jun 15, 2011
Politics & Policy

NIH awards $200M for translational research

NIH awarded a total of $200 million to fund translation research at five institutions as part of its Clinical and Translational Science Awards (CTSA) program. The institutions are: Pennsylvania State University; Milton S. Hershey Medical...
Items per page:
1 - 10 of 11